New hope for pancreatic cancer: targeted drug trial launches
NCT ID NCT07561463
First seen May 02, 2026 · Last updated Jun 23, 2026 · Updated 13 times
Summary
This study tests a drug called sacituzumab tirumotecan in 30 people with advanced pancreatic cancer that has worsened after at least one prior treatment. The drug is given by IV every two weeks and aims to shrink tumors by targeting a protein called TROP-2. Researchers will measure how many patients respond, how long they live, and what side effects occur.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sacituzumab tirumotecan
What this could lead to
If successful, this could provide a new treatment option for advanced pancreatic cancer patients who have run out of standard therapies.
What could go wrong
This is an early phase II trial with only 30 participants, so results may not apply broadly. The drug may cause side effects or fail to shrink tumors.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.